Pacira BioSciences Crescita futura
Criteri Future verificati 3/6
Si prevede che Pacira BioSciences aumenterà gli utili e i ricavi rispettivamente del 35.1% e 6.2% all'anno, mentre si prevede che l'EPS crescerà del 104.1% all'anno.
Informazioni chiave
35.1%
Tasso di crescita degli utili
104.11%
Tasso di crescita dell'EPS
| Pharmaceuticals crescita degli utili | 14.4% |
| Tasso di crescita dei ricavi | 6.2% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Good |
| Ultimo aggiornamento | 19 May 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Seeking Alpha • May 19
Pacira BioSciences: Exparel Still Supports My Original Bull Case
Summary PCRX remains a commercial non-opioid pain company built around Exparel, Zilretta, and Iovera. That’s why I think the most important catalysts for this stock, for better or worse, will be its upcoming 2026 pipeline readouts. But I reckon that PCRX’s overdependence on Exparel remains a factor worth considering, aside from other inherent biotech risks like patents and reimbursement policies, among others. Fortunately, PCRX’s recent pullback actually offers a discount on a relatively improved company compared to the first time I covered it. As such, I reiterate my “Buy” on PCRX. Read the full article on Seeking Alpha
Aggiornamento della narrazione • May 01
PCRX: Real World Procedure Data Will Support Future Upside Repricing
Analysts nudged their price target on Pacira BioSciences up by $2, citing slightly stronger modeled revenue growth of 17.50% and an 8.33% profit margin outlook, supported by recent real world data updates and mixed but active coverage on the stock. Analyst Commentary Recent research has been mixed, but the latest commentary highlights that bullish analysts are still finding reasons to lean constructive on Pacira BioSciences, especially around the updated revenue growth and margin framework that underpins the new price target.
Aggiornamento della narrazione • Apr 16
PCRX: Real World Hip Data And Activist Pressure Will Shape Outlook
Analysts have reduced their Pacira BioSciences price target by $2, citing updated real world data in hip arthroplasty and revisions to growth, margin, and future P/E assumptions. Analyst Commentary Bearish analysts are flagging that updated real world hip arthroplasty data has introduced more uncertainty into Pacira BioSciences' outlook, leading to more cautious assumptions around growth, margin profile, and future P/E levels.Aggiornamento della narrazione • Apr 01
PCRX: Higher 2026 Outlook And Activist Pressure Will Unlock Future Upside
Analysts have trimmed their Pacira BioSciences price target by $2, citing updated assumptions around faster revenue growth, a lower profit margin outlook, and a higher future P/E multiple. Analyst Commentary Despite the modest trim to the headline price target, bullish analysts see the updated assumptions as a way to reset expectations while keeping a constructive view on Pacira BioSciences.Aggiornamento della narrazione • Mar 17
PCRX: Future Outlook Weighs Activist Board Push Against Asia Licensing Upside
Analysts have reaffirmed their $22.00 price target for Pacira BioSciences, noting small adjustments to revenue growth, profit margin assumptions, and a slightly lower future P/E multiple to reflect updated expectations for the company’s earnings profile. What's in the News DOMA Perpetual Capital Management nominated three director candidates for the 2026 annual meeting and called for the immediate replacement of CEO Frank Lee, the appointment of an interim CEO, and a formal sale process for the business (Investor activism, March 12, 2026).Aggiornamento della narrazione • Mar 03
PCRX: Future Outlook Balances Asia Partnership Progress With Activist Pressure
Analysts have trimmed their price target on Pacira BioSciences from $24 to $22, reflecting updated assumptions that include a higher discount rate, more conservative revenue expectations, and lower projected profit margins, partly offset by a slightly higher future P/E multiple. What's in the News Issued full year 2026 earnings guidance, with total revenue expected in a range of $745 million to $770 million.Aggiornamento della narrazione • Feb 17
PCRX: Asia Partnership Will Drive Future Upside Potential
Analysts have kept their $38.00 price target for Pacira BioSciences steady, with only small tweaks to assumptions around revenue growth, profit margins and future P/E that support this unchanged view. What's in the News Pacira BioSciences entered an agreement with LG Chem that gives LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets.Aggiornamento della narrazione • Feb 02
PCRX: Asia Partnerships And Pipeline Progress Will Drive Future Upside Potential
Analysts have reiterated a US$38.00 price target for Pacira BioSciences, citing slightly updated assumptions for revenue growth, profit margin, and future P/E that collectively leave their overall valuation view unchanged. What's in the News Pacira entered an agreement with LG Chem, giving LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets, with Pacira receiving an upfront payment, transfer price, and tiered royalties while LG Chem handles regulatory filings in South Korea and Thailand within six months (Client Announcements).Aggiornamento della narrazione • Jan 19
PCRX: Asia Partnership And Pipeline Advances Will Drive Future Upside Potential
Narrative Update Analysts have kept their price target for Pacira BioSciences broadly steady around $38.00, citing slightly higher modeled revenue growth, a modestly lower profit margin outlook, and a similar forward P/E assumption. What’s in the News Pacira entered an agreement with LG Chem, granting LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets.Articolo di analisi • Jan 17
Revenues Working Against Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Share Price Following 28% Dive
Pacira BioSciences, Inc. ( NASDAQ:PCRX ) shareholders won't be pleased to see that the share price has had a very rough...Aggiornamento della narrazione • Jan 05
PCRX: Share Buybacks And Activist Pressure Will Support Future Upside Potential
Analysts have kept their fair value estimate for Pacira BioSciences steady at $38.00. The latest price target is grounded in updated assumptions for slightly different revenue growth, profit margin expectations, and a higher future P/E multiple.Aggiornamento della narrazione • Dec 14
PCRX: Activist Pressure And Share Buybacks Will Unlock Future Upside Potential
Analysts have modestly raised their price target on Pacira BioSciences to $38.00 from $36.00, citing expectations for slightly stronger long term profitability despite a somewhat more conservative revenue growth outlook and valuation multiple. What's in the News Activist investor DOMA Perpetual Capital Management sent a letter to Pacira's board urging the company to hire bankers and pursue a full sale process, citing persistent underperformance and overspending (Key Developments).Articolo di analisi • Nov 13
Pacira BioSciences' (NASDAQ:PCRX) Strong Earnings Are Of Good Quality
When companies post strong earnings, the stock generally performs well, just like Pacira BioSciences, Inc.'s...
Aggiornamento della narrazione • Aug 17
Policy Changes And Partnerships Will Expand Ambulatory Market Reach
The slight decrease in consensus revenue growth expectations and a lower future P/E multiple have led analysts to reduce their fair value estimate for Pacira BioSciences from $30.60 to $29.00. What's in the News Pacira completed a $50.04 million buyback, repurchasing 1,955,589 shares (4.23%) under its May 2025 authorization and previously completed a $25 million buyback (837,240 shares, 1.8%) under its May 2024 authorization.Articolo di analisi • Jun 11
Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Apr 09
Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act
Summary PCRX focuses on non-opioid pain management with Exparel, Zilretta, and iovera, delivering targeted pain relief with fewer side effects. A key secular tailwind for them comes from the NOPAIN Act, which creates separate reimbursement and grows access to non-opioid therapies. Also, PCRX’s PCRX-201 is a promising new gene therapy for knee osteoarthritis, which so far has shown promising results and targets a sizeable TAM. I also like how PCRX reached important patent settlements that secure its competitive prospects with Exparel’s exclusivity until 2030. In my view, PCRX remains undervalued at these levels, which is why I consider it a “Buy” despite its inherent biotech risks. Read the full article on Seeking AlphaArticolo di analisi • Apr 07
Pacira BioSciences, Inc. (NASDAQ:PCRX) Looks Inexpensive But Perhaps Not Attractive Enough
You may think that with a price-to-sales (or "P/S") ratio of 1.5x Pacira BioSciences, Inc. ( NASDAQ:PCRX ) is a stock...Seeking Alpha • Mar 14
Pacira BioSciences: Back On An Uptrend After Positive Developments
Summary Pacira BioSciences, Inc.'s stock is up 33% since my last “Buy” rating, driven by strategic moves and market overreaction correction. The company has secured a new patent for its lead pain therapeutic, Exparel, delaying generic market entrants, and potentially protecting its market share until mid-next decade. Vertex's Journavx launch may boost awareness for non-opioid pain relief, benefiting Pacira's Exparel under the NOPAIN Act. Pacira's new five-point plan aims for growth, profitability, and pipeline expansion, positioning it for potential blockbuster revenue and market leadership. The positive steps PCRX has taken since my last note means there is no change to my “buy” thesis. Read the full article on Seeking AlphaArticolo di analisi • Jan 30
Pacira BioSciences (NASDAQ:PCRX) Has A Rock Solid Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Jan 03
Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement
You may think that with a price-to-sales (or "P/S") ratio of 1.2x Pacira BioSciences, Inc. ( NASDAQ:PCRX ) is a stock...Seeking Alpha • Nov 25
Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses
Summary Pacira BioSciences markets and sells EXPAREL, a non-opioid pain relief therapy. The drug drives revenues of >$500m per annum, but a new generic version has been approved, while Pharma giant Vertex is close to having a similar drug approved. Pacira's share price has plummeted from >$80 in mid-2022 to ~$18 today, as the market sees little growth in the business and notes the competitive threats. The market may be a little too pessimistic - Vertex's drug is unproven in the market while generics may be held off for many more years. EXPAREL's peak years may still be ahead - PCRX stock could recoup some deserved value if it can share positive Q4 earnings, update on legal matters, and keep developing its pipeline. Read the full article on Seeking Alpha
Nuova narrazione • Sep 24
EXPAREL's Calculated Expansion And Innovative R&D Bolster Market Dominance Amidst Challenges
Expanding EXPAREL utilization in outpatient settings and through GPO partnerships aims to enhance revenue by increasing market penetration and affordability.Articolo di analisi • Sep 06
Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%
To the annoyance of some shareholders, Pacira BioSciences, Inc. ( NASDAQ:PCRX ) shares are down a considerable 34% in...Articolo di analisi • Jul 23
Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding
Pacira BioSciences, Inc. ( NASDAQ:PCRX ) shareholders that were waiting for something to happen have been dealt a blow...Articolo di analisi • Jun 07
These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 942 | 99 | 407 | 321 | 5 |
| 12/31/2027 | 831 | 70 | 186 | 198 | 6 |
| 12/31/2026 | 767 | 34 | 145 | 158 | 6 |
| 3/31/2026 | 735 | 5 | 133 | 142 | N/A |
| 12/31/2025 | 726 | 7 | 137 | 152 | N/A |
| 9/30/2025 | 717 | 21 | 124 | 141 | N/A |
| 6/30/2025 | 706 | -127 | 117 | 135 | N/A |
| 3/31/2025 | 703 | -104 | 159 | 176 | N/A |
| 12/31/2024 | 701 | -100 | 179 | 189 | N/A |
| 9/30/2024 | 695 | -91 | 194 | 204 | N/A |
| 6/30/2024 | 690 | 64 | 185 | 194 | N/A |
| 3/31/2024 | 682 | 70 | 173 | 185 | N/A |
| 12/31/2023 | 675 | 42 | 139 | 155 | N/A |
| 9/30/2023 | 666 | 7 | 130 | 149 | N/A |
| 6/30/2023 | 669 | -5 | 127 | 147 | N/A |
| 3/31/2023 | 669 | -10 | 105 | 134 | N/A |
| 12/31/2022 | 667 | 16 | 115 | 145 | N/A |
| 9/30/2022 | 654 | 21 | 93 | 126 | N/A |
| 6/30/2022 | 614 | 39 | 102 | 144 | N/A |
| 3/31/2022 | 580 | 38 | 104 | 144 | N/A |
| 12/31/2021 | 542 | 42 | 80 | 126 | N/A |
| 9/30/2021 | 513 | 62 | 98 | 149 | N/A |
| 6/30/2021 | 503 | 174 | 83 | 129 | N/A |
| 3/31/2021 | 443 | 148 | 39 | 83 | N/A |
| 12/31/2020 | 430 | 146 | 39 | 77 | N/A |
| 9/30/2020 | 421 | 126 | 28 | 56 | N/A |
| 6/30/2020 | 408 | -10 | 13 | 35 | N/A |
| 3/31/2020 | 435 | 0 | 58 | 73 | N/A |
| 12/31/2019 | 421 | -11 | N/A | 71 | N/A |
| 9/30/2019 | 394 | 2 | N/A | 66 | N/A |
| 6/30/2019 | 372 | 8 | N/A | 64 | N/A |
| 3/31/2019 | 354 | 7 | N/A | 55 | N/A |
| 12/31/2018 | 337 | 0 | N/A | 49 | N/A |
| 9/30/2018 | 321 | -4 | N/A | 45 | N/A |
| 6/30/2018 | 305 | -11 | N/A | 25 | N/A |
| 3/31/2018 | 292 | -33 | N/A | 15 | N/A |
| 12/31/2017 | 287 | -43 | N/A | 18 | N/A |
| 9/30/2017 | 280 | -51 | N/A | 18 | N/A |
| 6/30/2017 | 281 | -66 | N/A | 33 | N/A |
| 3/31/2017 | 280 | -54 | N/A | 37 | N/A |
| 12/31/2016 | 276 | -38 | N/A | 33 | N/A |
| 9/30/2016 | 273 | -36 | N/A | 33 | N/A |
| 6/30/2016 | 267 | -11 | N/A | 26 | N/A |
| 3/31/2016 | 256 | -3 | N/A | 26 | N/A |
| 12/31/2015 | 249 | 2 | N/A | 28 | N/A |
| 9/30/2015 | 241 | 10 | N/A | 26 | N/A |
| 6/30/2015 | 231 | 4 | N/A | 29 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: La crescita prevista degli utili di PCRX ( 35.1% all'anno) è superiore al tasso di risparmio ( 3.5% ).
Guadagni vs Mercato: Si prevede che gli utili di PCRX ( 35.1% all'anno) cresceranno più rapidamente del mercato US ( 16.8% all'anno).
Guadagni ad alta crescita: Si prevede che gli utili di PCRX cresceranno in modo significativo nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di PCRX ( 6.2% all'anno) crescerà più lentamente rispetto al mercato US ( 11.6% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di PCRX ( 6.2% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di PCRX è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/20 14:34 |
| Prezzo dell'azione a fine giornata | 2026/05/20 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Pacira BioSciences, Inc. è coperta da 29 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Jenna Davidner | Barclays |
| Anita Dushyanth | Berenberg |
| Gary Nachman | BMO Capital Markets Equity Research |